| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/23/2022 | 34.27% | Roth Capital | $85 → $90 | Maintains | Buy |
| 11/21/2022 | 79.02% | Barclays | $150 → $120 | Maintains | Overweight |
| 10/25/2022 | 123.78% | Barclays | $157 → $150 | Maintains | Overweight |
| 09/02/2022 | 161.08% | Roth Capital | $185 → $175 | Maintains | Buy |
| 07/05/2022 | 134.22% | Barclays | $165 → $157 | Maintains | Overweight |
| 05/16/2022 | 93.94% | Stephens & Co. | $153 → $130 | Maintains | Overweight |
| 02/22/2022 | 93.94% | Benchmark | $180 → $130 | Maintains | Buy |
| 02/18/2022 | 146.16% | Barclays | $185 → $165 | Maintains | Overweight |
| 09/22/2021 | 168.54% | Barclays | $174 → $180 | Maintains | Overweight |
| 07/30/2021 | 183.46% | Roth Capital | $200 → $190 | Maintains | Buy |
| 05/04/2021 | 183.46% | Barclays | $198 → $190 | Maintains | Overweight |
| 02/04/2021 | 195.39% | Barclays | $145 → $198 | Maintains | Overweight |
| 02/04/2021 | 198.37% | Roth Capital | $195 → $200 | Maintains | Buy |
| 02/04/2021 | 362.48% | HC Wainwright & Co. | $229 → $310 | Maintains | Buy |
| 10/21/2020 | 190.91% | Craig-Hallum | $215 → $195 | Maintains | Buy |
| 09/29/2020 | 190.91% | Roth Capital | $190 → $195 | Reiterates | → Buy |
| 08/04/2020 | 116.32% | Barclays | $134 → $145 | Maintains | Overweight |
| 04/08/2020 | 241.64% | HC Wainwright & Co. | $237 → $229 | Maintains | Buy |
| 03/24/2020 | — | Argus Research | Downgrades | Buy → Hold | |
| 03/10/2020 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 02/06/2020 | — | Benchmark | Initiates Coverage On | → Buy | |
| 09/19/2019 | 96.93% | Barclays | $110 → $132 | Upgrades | Equal-Weight → Overweight |
| 08/05/2019 | 64.11% | Barclays | $131 → $110 | Maintains | Equal-Weight |
| 06/11/2019 | 95.43% | Barclays | → $131 | Initiates Coverage On | → Equal-Weight |
| 09/19/2018 | 302.8% | HC Wainwright & Co. | $257 → $270 | Maintains | Buy |
| 08/17/2018 | 281.92% | Goldman Sachs | → $256 | Initiates Coverage On | → Neutral |
| 08/08/2018 | — | Roth Capital | Downgrades | Buy → Neutral | |
| 06/21/2018 | 287.89% | Argus Research | → $260 | Initiates Coverage On | → Buy |
| 03/07/2018 | 171.52% | HC Wainwright & Co. | $170 → $182 | Maintains | Buy |
| 01/24/2018 | 153.62% | HC Wainwright & Co. | $159 → $170 | Maintains | Buy |
What is the target price for Ligand Pharmaceuticals (LGND)?
There is no price target for Ligand Pharmaceuticals
What is the most recent analyst rating for Ligand Pharmaceuticals (LGND)?
There is no analyst for Ligand Pharmaceuticals
When is the next analyst rating going to be posted or updated for Ligand Pharmaceuticals (LGND)?
There is no next analyst rating for Ligand Pharmaceuticals
Is the Analyst Rating Ligand Pharmaceuticals (LGND) correct?
There is no next analyst rating for Ligand Pharmaceuticals